Sanofi (NASDAQ:SNY) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on Sanofi, with 10 hold, three buy and two strong-buy ratings among 15 brokerages. The average 12-month price target is $49.50, compared with shares opening at $43.08.
• Sanofi reported stronger-than-expected second-quarter results, driven by Dupixent sales exceeding €5 billion, and raised its 2026 outlook to approximately 10% sales growth excluding currency effects.
• Despite the earnings strength, investors remain concerned about pipeline setbacks and weak R&D execution, which could affect future product launches and offset Dupixent’s momentum.

Sanofi (NASDAQ:SNY - Get Free Report) has been assigned a consensus recommendation of "Hold" from the fifteen brokerages that are presently covering the firm, MarketBeat.com reports. Ten equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $49.50.

Several analysts have recently issued reports on the stock. Morgan Stanley set a $49.00 price target on shares of Sanofi in a research report on Wednesday, July 8th. BNP Paribas Exane lowered shares of Sanofi from an "outperform" rating to a "neutral" rating and set a $50.00 target price on the stock. in a report on Monday, April 20th. Citigroup reissued a "neutral" rating on shares of Sanofi in a research report on Monday, April 13th. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Argus raised Sanofi to a "strong-buy" rating in a research report on Monday, April 27th.

Institutional Investors Weigh In On Sanofi

A number of hedge funds have recently bought and sold shares of the stock. Flagship Harbor Advisors LLC acquired a new position in shares of Sanofi during the fourth quarter worth about $25,000. Physician Wealth Advisors Inc. raised its holdings in Sanofi by 180.5% in the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company's stock valued at $28,000 after acquiring an additional 379 shares in the last quarter. Western Wealth Management LLC acquired a new stake in Sanofi in the first quarter valued at approximately $29,000. Leonteq Securities AG lifted its stake in Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company's stock worth $29,000 after acquiring an additional 297 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC purchased a new position in Sanofi in the third quarter worth approximately $29,000. Institutional investors and hedge funds own 14.03% of the company's stock.

Trending Headlines about Sanofi

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi reported second-quarter earnings of $1.19 per share, exceeding the $1.10 analyst consensus, while revenue rose 16% year over year to $14.04 billion, above expectations of $13.02 billion. Sanofi quarterly earnings report
• Positive Sentiment: Strong demand for blockbuster immunology drug Dupixent drove the results, with quarterly sales surpassing €5 billion for the first time. The performance led Sanofi to raise its 2026 outlook, targeting roughly 10% sales growth excluding currency effects and slightly faster growth in business earnings per share. Sanofi raises sales outlook on Dupixent strength
• Neutral Sentiment: Unusually high options activity showed traders purchased 4,046 call options, 74% above average daily volume. This may indicate increased bullish speculation, but it does not necessarily signal a change in the company’s fundamentals.
• Negative Sentiment: Management acknowledged that weak decision-making and execution hurt the pipeline. The new CEO plans to overhaul and prioritize R&D, raising concerns about the timing and strength of future product launches. Sanofi discusses pipeline and R&D discipline
• Negative Sentiment: The positive earnings and guidance news was overshadowed by pipeline setbacks, leaving investors focused on whether Dupixent’s momentum can offset longer-term portfolio risks. Sanofi beats earnings but faces pipeline setbacks

Sanofi Stock Performance

Shares of SNY stock opened at $43.08 on Monday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. The firm's 50 day moving average price is $43.43 and its 200-day moving average price is $45.19. Sanofi has a one year low of $40.89 and a one year high of $52.68. The firm has a market cap of $104.44 billion, a P/E ratio of 22.55, a P/E/G ratio of 1.15 and a beta of 0.35.

Sanofi Company Profile

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.